BPC-157

BPC-157 is a synthetic 15–amino-acid peptide (a “pentadecapeptide”) corresponding to a partial sequence of body protection compound (BPC), a protein isolated from human gastric juice. In the research literature it is described as unusually stable — reportedly resistant to degradation in gastric acid — which is one reason it is so widely used as a reference “cytoprotective” compound in preclinical work. No single high-affinity receptor has been firmly established; instead, reviews characterise its activity as pleiotropic, spanning vascular, connective-tissue, gastrointestinal, and nervous-system models, and frequently framed in terms of growth-factor and nitric-oxide signalling. [1][3] The overwhelming majority of this evidence comes from rodent and in-vitro studies; efficacy has not been established in humans. [1]

The earliest and most extensive BPC-157 literature concerns the gastrointestinal tract. In rodent models of gastric and intestinal lesions, researchers have reported preservation of mucosal integrity and accelerated closure of experimentally induced ulcers and fistulas, effects discussed in the framework of Robert's “cytoprotection” and Selye's stress-response biology. [3][4] Proposed mechanisms in these reports centre on the nitric-oxide (NO) system and on maintenance of vascular and epithelial function under stress. This gastrointestinal focus is consistent with the peptide's origin as a gastric-juice–derived sequence. [3]

A recurring theme across the in-vitro literature is angiogenesis — the formation of new blood vessels. In cultured human umbilical vein endothelial cells (HUVECs), studies have reported increased proliferation, migration, and tube formation alongside upregulation of vascular endothelial growth factor (VEGF). [6] Mechanistic work in endothelial cells and chick-embryo models has associated these effects with activation and up-regulation of VEGF receptor-2 (VEGFR2) and downstream nitric-oxide signalling. [5] In injury models this pro-angiogenic activity is often linked to the idea of vascular “running” — directed outgrowth of vessels toward ischemic or damaged tissue. [5][6]

Because tendons and ligaments are poorly vascularised and slow to repair, they are a frequent subject of BPC-157 research. In rat tendon studies, the peptide has been reported to promote outgrowth and migration of tendon fibroblasts, improve cell survival under oxidative (H₂O₂) stress, and increase F-actin formation. [7] Investigators have linked the migratory effect to phosphorylation of focal adhesion kinase (FAK) and paxillin — the “FAK–paxillin pathway” — without changing total protein levels. [7] Reviews of the broader musculoskeletal literature describe consistent healing signals across tendon, ligament, bone, and skeletal-muscle injury models, and separate work has examined striated, smooth, and cardiac muscle preparations. [1][8]

In dermal wound models — including incisional, excisional, and alkali-burn injuries in rodents — BPC-157 has been associated with faster wound closure, improved granulation-tissue formation, re-epithelialisation, and collagen organisation. [2][6] At the signalling level, one study reported regulation of extracellular signal-regulated kinases 1/2 (ERK1/2) and their downstream targets c-Fos, c-Jun, and Egr-1 — transcriptional regulators tied to cell growth, migration, and angiogenesis. [6] As elsewhere, these are controlled laboratory observations in animal and cell-culture systems rather than clinical findings. [2]

Preclinical work has extended to the central and peripheral nervous system. In a murine traumatic-brain-injury model, researchers reported attenuated lesion severity and reduced brain edema in BPC-157–treated animals. [9] A dedicated review summarises additional nervous-system models, including nerve-injury and ischemia paradigms. [10] More recent literature situates these observations within a proposed bidirectional gut–brain / brain–gut axis, consistent with the peptide's gastrointestinal origins. [11]

Two properties make BPC-157 a common reference compound in peptide research: its reported stability (including in gastric juice) and the breadth of models in which it has been studied. [1][3] The literature is dominated by a relatively small number of research groups, and reviewers consistently note that findings are preclinical and not yet confirmed in humans. [1] These materials are supplied strictly for in-vitro and laboratory research; nothing here should be read as a therapeutic claim.